| Julie Verespej, | |
|
101 Eagle Trace Dr, Medford, OR 97504-8087 | |
| (541) 261-4534 | |
| Not Available |
| Full Name | Julie Verespej |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 101 Eagle Trace Dr, Medford, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295101517 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 200230077LPN (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Julie Verespej, 101 Eagle Trace Dr, Medford, OR 97504-8087 Ph: (541) 261-4534 | Julie Verespej, 101 Eagle Trace Dr, Medford, OR 97504-8087 Ph: (541) 261-4534 |
News Archive
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Viread® (tenofovir disoproxil fumarate).
Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug.
In the Western Pacific Region, transmission of HIV/AIDS and other infections such as hepatitis B and C through blood transfusion remains a serious threat. It is particularly acute in areas where prevalence of these diseases is high and access to safe blood is limited.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.
› Verified 3 days ago
Patricia Lancaster, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1861 Pinedale St, Medford, OR 97504 Phone: 541-274-0733 | |
Sarah Cathlean Moreno, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2825 E Barnett Rd, Medford, OR 97504 Phone: 541-857-7000 | |
Keriann Ensworth, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Murphy Rd, Medford, OR 97504 Phone: 541-772-2763 Fax: 541-734-3164 | |
Lesie Wobig, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Murphy Rd, Medford, OR 97504 Phone: 541-772-2763 | |
Alice Marie Velasquez, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Murphy Rd, Medford, OR 97504 Phone: 541-772-2783 | |
Tracy Lawton, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Murphy Rd, Medford, OR 97504 Phone: 541-772-2763 Fax: 541-734-3164 | |
Amy Renee Goodwin, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 777 Murphy Rd, Medford, OR 97504 Phone: 541-772-2763 Fax: 541-734-3164 |